Improving care for patients with chronic heart failure in the community: the importance of a disease management program.

STUDY OBJECTIVE Utilizing a comparison group of patients with congestive heart failure (CHF) discharged to their primary care physicians, we sought to determine if disease management in a short-term, aggressive-intervention heart failure clinic (HFC) following hospital discharge is associated with improved outcomes. DESIGN Chart review. SETTING An integrated health-care center serving a tristate area. PATIENTS Inclusion criteria were discharge from the hospital with a primary diagnosis of CHF, outpatient follow-up within the hospital system, and the presence of left ventricular systolic dysfunction as the basis for CHF. Patients were categorized into group 1 if they were referred to the HFC after hospital discharge, and into group 2 if follow-up care was provided by their primary care physician. MEASUREMENTS AND RESULTS There were 38 patients in group 1 and 63 patients in group 2. There was a trend toward a shorter time to the first outpatient visit following discharge (11 days vs 15 days, p = 0.09), more outpatient visits within 90 days (10 visits vs 2 visits, p < 0.001), and more patient-initiated contacts (four contacts vs one contact, p = < 0.001) in group 1 compared to group 2, respectively. The combined hospital readmission and mortality rate at 90 days (10% vs 30%, p < 0.018) and 1 year (21% vs 43%, p < 0.02) was lower in group 1. There was a 77% relative risk reduction for 30-day hospital readmission in favor of group 1, and a statistically lower rate of readmissions at 90 days and 1 year. Utilization and maintenance of standardized CHF medications were significantly higher in patients who attended the HFC. CONCLUSIONS A comprehensive disease management program for patients discharged with a diagnosis of CHF resulted in fewer rehospitalizations and improved event-free survival compared to patients followed up by their primary care physicians.

[1]  C. O'connor,et al.  The benefit of implementing a heart failure disease management program. , 2001, Archives of internal medicine.

[2]  K. Akosah,et al.  Chronic heart failure in the community: missed diagnosis and missed opportunities. , 2001, Journal of cardiac failure.

[3]  R. Lancashire,et al.  Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.

[4]  D R Jacobs,et al.  Trends in Acute Coronary Heart Disease Mortality, Morbidity, and Medical Care From 1985 Through 1997: The Minnesota Heart Survey , 2001, Circulation.

[5]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[6]  J. Cutler,et al.  Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. , 2000, Circulation.

[7]  N. Sheynberg,et al.  Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure , 2000, Clinical cardiology.

[8]  F. Zannad,et al.  Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. , 2000, American heart journal.

[9]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[10]  M. Rich,et al.  Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. , 1999, American heart journal.

[11]  D. Baker,et al.  Variations in family physicians' and cardiologists' care for patients with heart failure. , 1999, American heart journal.

[12]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[13]  L. Erhardt,et al.  Cost effective management programme for heart failure reduces hospitalisation , 1998, Heart.

[14]  D. DeMets,et al.  Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF) , 1997 .

[15]  G. Fonarow,et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.

[16]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[17]  E. Philbin,et al.  Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.

[18]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .